Zacks Research Has Negative Outlook of Teleflex Q3 Earnings

Teleflex Incorporated (NYSE:TFX) – Investment analysts at Zacks Research reduced their Q3 2024 earnings per share estimates for shares of Teleflex in a research note issued on Wednesday, October 23rd. Zacks Research analyst R. Department now anticipates that the medical technology company will post earnings per share of $3.36 for the quarter, down from their previous estimate of $3.37. The consensus estimate for Teleflex’s current full-year earnings is $13.97 per share. Zacks Research also issued estimates for Teleflex’s Q4 2024 earnings at $3.91 EPS, Q2 2025 earnings at $3.74 EPS, Q1 2026 earnings at $3.99 EPS and Q3 2026 earnings at $4.14 EPS.

Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, August 1st. The medical technology company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.33 by $0.09. The business had revenue of $749.70 million during the quarter, compared to analyst estimates of $762.98 million. Teleflex had a net margin of 8.76% and a return on equity of 14.51%. The company’s revenue for the quarter was up .9% on a year-over-year basis. During the same period in the prior year, the business earned $3.41 EPS.

Other research analysts also recently issued research reports about the company. Royal Bank of Canada upped their target price on Teleflex from $260.00 to $275.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Piper Sandler upgraded Teleflex from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $205.00 to $245.00 in a research report on Monday, July 1st. Truist Financial increased their price objective on Teleflex from $247.00 to $255.00 and gave the stock a “hold” rating in a report on Monday, October 14th. Finally, Stephens boosted their target price on shares of Teleflex from $275.00 to $290.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $268.86.

Teleflex Price Performance

TFX stock opened at $237.82 on Thursday. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.58 and a quick ratio of 1.44. Teleflex has a 1 year low of $177.63 and a 1 year high of $257.85. The firm has a 50-day moving average of $241.19 and a 200 day moving average of $223.48. The company has a market cap of $11.21 billion, a P/E ratio of 42.70, a PEG ratio of 2.15 and a beta of 1.16.

Teleflex Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 16th. Shareholders of record on Thursday, August 15th were paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date was Thursday, August 15th. Teleflex’s payout ratio is 24.42%.

Insiders Place Their Bets

In related news, Director Stuart A. Randle sold 2,674 shares of the stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $238.93, for a total transaction of $638,898.82. Following the sale, the director now directly owns 5,496 shares of the company’s stock, valued at approximately $1,313,159.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.43% of the company’s stock.

Institutional Trading of Teleflex

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in shares of Teleflex by 1.8% during the 1st quarter. Vanguard Group Inc. now owns 5,550,727 shares of the medical technology company’s stock valued at $1,255,408,000 after acquiring an additional 96,711 shares during the last quarter. Janus Henderson Group PLC raised its stake in Teleflex by 12.0% during the 1st quarter. Janus Henderson Group PLC now owns 5,409,317 shares of the medical technology company’s stock valued at $1,223,424,000 after buying an additional 581,312 shares during the last quarter. Cooke & Bieler LP lifted its holdings in shares of Teleflex by 23.3% during the 2nd quarter. Cooke & Bieler LP now owns 912,797 shares of the medical technology company’s stock valued at $191,989,000 after buying an additional 172,335 shares during the period. TD Asset Management Inc boosted its stake in shares of Teleflex by 12.0% in the 2nd quarter. TD Asset Management Inc now owns 456,081 shares of the medical technology company’s stock worth $95,928,000 after buying an additional 48,832 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Teleflex by 6.6% in the second quarter. Bank of New York Mellon Corp now owns 425,647 shares of the medical technology company’s stock worth $89,526,000 after acquiring an additional 26,325 shares during the period. Institutional investors own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.